DISTINCTIVE

seconD- line folfiri aflIbercept in proSpecTIvely stratified, anti-egfr resistaNt, metastatic coloreCTal  cancer patIents with ras validated wild typstatus (distinctive)

AFLIBERCEPT POST ANTI-EGFR IN CCR

· Circulating pro-angiogenic factors dynamic changes during treatment with FOLFIRI-aflibercept: interim analysis of DISTINCTIVE study - a GISCAD trial

Scarica il file  

· Monocytes to red blood cells ratio (MRR): an innovative haematologic prognostic parameter in metastatic colorectal cancer patients treated with FOLFIRI-aflibercept - a subgroup analysis from the DISTINCTIVE study - a GISCAD trial

Scarica il file